Bernard Peperstraete

Bernard Peperstraete is a seasoned medical entrepreneur and the co-founder and CEO of Acuamark Diagnostics, Inc., a company focused on early cancer detection through innovative blood-based diagnostics.12 With over 20 years of experience in the life sciences sector, Bernard has held various leadership and board positions, including roles at ACT Biotech, NGN Capital, and Exosome Diagnostics.2

Before founding Acuamark, Bernard led ACT Biotech, which was later acquired by Eddingpharm, and worked in healthcare venture capital as a Partner at NGN Capital.1 He has also served on the boards of several companies such as Potentia Pharma and was involved in significant transactions with companies like MaxCyte and Santhera.1

Bernard holds an MD from Katholieke Universiteit Leuven and an MBA from Harvard Business School. His early career included roles at Novartis in Basel and as Deputy Director at Tan Tock Seng Hospital in Singapore during the SARS crisis. Additionally, he co-founded a contract research business in Singapore and managed the HIV business unit at Bristol Myers & Squibb in Singapore.12